FDA Expands Bladder Cancer Regimen - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Bladder Cancer Regimen

  • by Kathryn Wighton

  • July 10, 2026

Related Content

Identity Formation May Shape Residency Emotions

A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

Poor Diet Quality Linked to Oral Cancer

Large prospective cohort data showed stronger associations among women without substantial tobacco or alcohol exposure.